IPAC-RS is an international association that seeks to advance the science, and especially the regulatory science, of orally inhaled and nasal drug products (OINDP) by collecting and analyzing data, and conducting joint research and development projects. Our members include innovator and generic companies that develop, manufacture or market orally inhaled and nasal drug products for local and systemic treatment of a variety of debilitating diseases such as asthma, chronic obstructive pulmonary disease and diabetes. We aim to build consensus and contribute to effective regulations and standards by sharing the results of our research through conferences, technical journals, and discussions with regulatory bodies.
IPAC-RS represents the interests of its members to international authorities and standard-setting bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, the United States Pharmacopeia (USP), the International Conference on Harmonization (ICH), the International Organization for Standardization (ISO), and regulatory agencies in other world regions. IPAC-RS also collaborates with trade associations and academic researchers around the globe.
The Consortium is governed by the Board of Directors, which is comprised of representatives from each member company. Technical work is carried out through working groups and technical committees established by the Board for specific initiatives. The IPAC-RS Secretariat, Drinker Biddle & Reath LLP, provides project management, administrative and other assistance for all projects.